The purpose of this research is to determine whether peanut consumption improves indicators of cardiovascular disease (CVD) risk in human subjects following the consumption of study foods.
Inclusion Criteria:
Exclusion Criteria:
Less than 18 and over 65 years old
Pregnant or lactating women
Adults who rely on prescription medication that may influence study variables, apart from birth control
BMI < 18.5 kg/m2 and > 39.9 kg/m2
Smokers who currently use tobacco- or marijuana-containing products including e-cigarettes, vape pens, pod mods, tanks, and electronic nicotine delivery devices (ENDS)
Habitual consumption of nuts, nut butters, nut powders, nut side dishes, nut bars or other nut products
Known food allergies (milk, eggs, fish, shellfish, tree nuts, peanuts, wheat, soybeans, sesame, corn) due to samples not prepared in a hypoallergenic environment
Currently living in close contact with individuals who have an allergy to peanuts, in order to avoid exposing these individuals to an allergen
Self-reported history of difficulties with blood drawing procedures including prior fainting or dizziness, or veins assessed as not suitable for four separate venipunctures by licensed phlebotomist
Diagnosed active chronic diseases for which the individual is currently taking daily medication, including but not limited to:
Recent minor surgery (within 4 weeks) or major surgery (within 16 weeks)
Known gallbladder disease or history of cholecystectomy
History of gastrointestinal surgery, including gastric bypass surgery or resection
Diagnosis of irritable bowel syndrome
Recent antibiotic therapy (within 4 weeks)
Recent hospitalization (within 4 weeks)
Current participation in another research study
Has HIV/AIDS, hepatitis, or another disease that affects the immune system
Gives regular blood donations and is unwilling to stop during the study
Blood Pressure ≥ 140 mmHg systolic or 90 mmHg diastolic
Current diagnoses of an eating disorder (ex. anorexia, bulimia, etc.)
High - very high triglyceride levels: ≥ 300 mg/dL
Adults who are unable to consent, individuals who are not yet adults (infants, children and teenagers), pregnant women and prisoners will be excluded from participation in the study
Participants who are unwilling to collect and transport urine, stool and saliva samples
Abnormal hemoglobin and/or hematocrit levels
Abnormal liver function (defined as liver enzymes that are >200% of upper limit (ALT upper limit is 43 U/L or Aspartate transaminase (AST) upper limit is 54 U/L)
Unwillingness to discontinue probiotic, prebiotic, fiber, or other supplements (except RDA-level vitamin and mineral supplements) during the study
Unwilling to consume study foods
Alcohol consumption > 20 g/day
elbonnel@ucdavis.edu530-752-4184
Participants will be asked to consume 42g of peanuts with skin daily for 4 weeks. Following a 4-week washout, the participant will then be asked to consume 45g of corn chips daily for 4 weeks.
The participant will be asked to consume 45g of corn chips daily for 4 weeks. Following a 4-week washout, the participant will be then asked to consume 42g of peanuts with skin daily for 4 weeks.
iosummerssteffes@ucdavis.edu530-754-8544
Davis, California 95616, United States
elbonnel@ucdavis.edu530-752-4184
iosummerssteffes@ucdavis.edu530-754-8544
Effects of Peanuts on Immunity and Cardiometabolic Risk Factors
Effects of Peanut Consumption on Postprandial Inflammation, Glucose and Triglycerides
The Anti-Inflammatory Effects of Exercise and Peanut Consumption
Peanuts and Neurocognitive / Cardiovascular Health in Black Individuals
Peanuts for Cardiometabolic, Brain, and Intestinal Health
Eating Peanuts for Health
Effects of Peanut Intake on Cognitive Functions
The Effects of Peanuts and Peanut Products on Glucose Control and Vascular Function